Plus   Neg

Cummins To Cut Structural Costs In 2020; Launching New Power Business

At a meeting with analysts and shareholders, Mark Smith, CFO of Cummins Inc. (CMI), stated that the company is prepared for a cyclical slowdown in 2020. The company is taking steps to lower its cost base, while continuing to invest in the new products and services. The company plans to reduce structural costs by $250 million to $300 million in 2020.

Cummins Inc. is launching new Power business which includes existing electrification business as well as fuel cell and hydrogen production technologies. Tony Satterthwaite, President and COO, said that while battery and fuel cell technologies have been a clear focus of Cummins, its investments in diesel and natural gas platforms would continue in order to achieve improved fuel economy and lower emissions.

"While we do anticipate a shift towards electrification in some markets over the coming years, diesel will be the primary source of energy in commercial vehicles for many years to come," Satterthwaite said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT